Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular benefits in type 2 diabetes, but none of the cardiovascular trials studied atrial fibrillation/atrial flutter (AF) as a primary endpoint
A measurement instead of a mystery
Rothberg, MD, a clinical professor at the University of Michigan, specializing in treating overweight and obesity
In the realm of cell-based therapies and antibodydrug conjugates (ADCs), CT041, a CLDN18.2-targeted CAR-T product, is being studied in gastrointestinal cancers (NCT04404595), while enfortumab vedotin, targeting Nectin-4, is under investigation for metastatic castration-resistant prostate cancer (NCT04754191)
Although the drug is currently captured in Schedule 4 (prescription only medications) of the Therapeutic Goods Administrations Poisons Standard, no products containing Melanotan are registered for use in Australia